ImmuCell Corporation
Price Action
Technical Summary
STAGE 2 UPTRENDImmuCell Corporation is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 91), indicating clear outperformance against the broad market. Earnings growth of 31% provides fundamental context to the price action. Investors should exercise caution due to high volatility (51% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $9.86 | +4.88% | ABOVE |
| 50 SMA | $9.47 | +9.22% | ABOVE |
| 100 SMA | $8.08 | +27.91% | ABOVE |
| 150 SMA | $7.41 | +39.48% | ABOVE |
| 200 SMA | $7.06 | +46.53% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ICCC in an uptrend right now?
ICCC has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ICCC is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is ICCC overbought or oversold?
ICCC's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.
Is ICCC outperforming the market?
ICCC has a Relative Strength (RS) Rating of 91 out of 99. Yes, ICCC is a market leader, outperforming 91% of all stocks over the past 12 months.
Where is ICCC in its 52-week range?
ICCC is trading at $10.34, which is 93% of its 52-week high ($11.16) and 88% above its 52-week low ($4.52).
How volatile is ICCC?
ICCC has a Beta of 0.58 and 52-week volatility of 51%. It's less volatile than the S&P 500 - generally more stable.